Penserra Capital Management’s GSK GSK Stock Holding History

Penserra Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,771	Closed	-$240K	–	1286
2023 Q1	$240K	Buy	6,771 +3,746	+124%	+$131K	0.01%	653
2022 Q4	$106K	Buy	3,025 +2,016	+200%	+$67.2K	﹤0.01%	802
2022 Q3	$29K	Sell	1,009 -1,751	-63%	-$66.4K	﹤0.01%	880
2022 Q2	$150K	Buy	+2,760	New	+$152K	﹤0.01%	711

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Penserra Capital Management's GSK Position: Q2 2023 in Review

Penserra Capital Management sold out of GSK (GSK) in Q2 2023, closing a stake of 6,771 shares — an estimated $240K sold.

Penserra Capital Management first reported a position in GSK in Q2 2022 and held it in 4 quarters. The position peaked at $240K in Q1 2023. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Penserra Capital Management reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Penserra Capital Management sold 6,771 GSK shares in Q2 2023, an estimated $240K.
Penserra Capital Management first reported a position in GSK in Q2 2022 and held it in 4 quarters.
Penserra Capital Management's GSK position peaked at $240K in Q1 2023.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Penserra Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.